ActivX Biosciences, Inc.

SAN DIEGO--(BUSINESS WIRE)-- Actio Biosciences, Inc., a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors. Dr. Cravatt is professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease. “By combining genuine expertise across biology, chemistry and genetics, Ben has pioneered an approach to drug discovery and development that sits at the heart of Actio’s mission,” said David Goldstein, Ph.D., co-founder and CEO of Actio. “We are thrilled to welcome Ben to our board and look forward to working together to discover and develop new life-changing medicines.” “Years of research has taught us that the best targets are those supported by human genetics – and it is becoming clear that specific kinds of genetic information are especially informative,” said Dr. Cravatt. “Actio’s laser-focused approach targeting genes responsible for rare devastating diseases promises new treatments for those diseases and a powerful framework for rational expansion to more common indications sharing mechanistic biology.” In addition to his role at Scripps, Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals) and Vividion Therapeutics (acquired by Bayer AG). His honors include a Wolf Prize in Chemistry, a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in biological sciences and a B.A. in history. He received a Ph.D. from The Scripps Research Institute (TSRI) in 1996 and joined the faculty at TSRI in 1997. About Actio Biosciences Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Founded in October 2021, the San Diego-based company is led by leaders in genetics and drug development and backed by top healthcare investors. For more information, please visit ActioBiosciences.com.

DUBLIN, June 30, 2023 /PRNewswire/ -- The "Global Proteomics Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Proteomics Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies. Trends in proteomics dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 600 proteomics deal records and contract documents where available The leading proteomics deals by value since 2010 Most active proteomics dealmakers since 2010 The leading proteomics partnering resources The Global Proteomics Partnering Terms and Agreements report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of proteomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in proteomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading proteomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active proteomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in proteomics dealmaking with a brief summary followed by a comprehensive listing of proteomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by Proteomics partnering company A-Z, deal type definitions and proteomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in proteomics partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of proteomics technologies and products. Key Topics Covered Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in proteomics dealmaking 2.1. Introduction 2.2. Proteomics partnering over the years 2.3. Most active proteomics dealmakers 2.4. Proteomics partnering by deal type 2.5. Proteomics partnering by therapy area 2.6. Deal terms for proteomics partnering 2.6.1 Proteomics partnering headline values 2.6.2 Proteomics deal upfront payments 2.6.3 Proteomics deal milestone payments 2.6.4 Proteomics royalty rates Chapter 3 - Leading proteomics deals 3.1. Introduction 3.2. Top proteomics deals by value Chapter 4 - Most active proteomics dealmakers 4.1. Introduction 4.2. Most active proteomics dealmakers 4.3. Most active proteomics partnering company profiles Chapter 5 - Proteomics contracts dealmaking directory 5.1. Introduction 5.2. Proteomics contracts dealmaking directory Chapter 6 - Proteomics dealmaking by technology type Appendices Appendix 1 - Proteomics deals by company A-Z Appendix 2 - Proteomics deals by stage of development Appendix 3 - Proteomics deals by deal type Appendix 4 - Proteomics deals by therapy area Deal type definitions Companies Mentioned 3SBio 20/20 BioResponse 21st Century Biochemicals A*STAR Bioinformatics Institute A*STAR Genome Institute of Singapore A*STAR Institute of Microelectronics (IME) AB Analitica Abbvie Abcam Ablynx Abnova Abraxis BioScience Absorption Systems Abt Bio Pharma Solutions Academy for Medical Development & Collaboration Acceleron Pharma Acella Pharmaceuticals ACGT Activiomics ActivX Biosciences ADC Biotechnology Adeona Pharmaceuticals Adimab Aduro BioTech Advaita Advanced Biological Laboratories Advanced BioScience Laboratories Advanced Manufacturing Fund Advinus Therapeutics Aelan Cell Technologies Aestus Therapeutic AEterna Zentaris Affibody Affomix Affymetrix Agilent Technologies AGTC Aileron Therapeutics Ajinomoto AminoScience Alamar Biosciences Albumedix Alexion Pharmaceuticals Allergan Allozyne Almac Diagnostics Almac Group Almirall Alnylam Pharmaceuticals Althea Technologies Altus Pharmaceuticals Alzheimers Research UK Amarantus BioSciences Ambergen Ambrx American College of Cardiology American CryoStem American Health Assistance Foundation Amgen AmorChem Amplimmune Amunix Analytical Testing Laboratory AnaSpec Anchor Therapeutics Angel Biotechnology Anteo Diagnostics Anthera Pharmaceuticals Antigen Discovery Antitope Apeiron Biologics Applied Proteomics Arbor Vita Arbutus Arecor Ariadne Genomics ArmaGen Arrayit Artes Biotechnology Aspera Astellas Pharma AstraZeneca Asuragen ATUM Auburn University Aurigene Discovery Technologies Aushon BioSystems Autism Speaks Autogenesis Auven Therapeutics Avera Heart Hospital of South Dakota Avid Bioservices AvidBiotics Avila Therapeutics Avraham Pharmaceuticals Axil Scientific BaroFold Batavia Biosciences Baxter International Bayer Bayer CropScience Bayer Schering Pharma Baylor College of Medicine BellBrook Labs Bellus Health Berg BGI Americas BG Medicine Bicycle Therapeutics Bill and Melinda Gates Foundation Bio-Techne BioAtla Biocartis Biocius Life Sciences Biocrates Biodesix Bioeasy Diagnostica BioFocus Biogen Biognosys BioGrammatics Biomodels BioNova Cientifica Biopharm BioSante Pharmaceuticals BioSeek Bio Sidus Argentina BioSilta BioSystem Development Biotage Biotechnology and Biological Sciences Research Council (BBSRC) Biotechnology Value Fund Biotest bioVidria BioWa Bioyong BluePen Biomarkers Blue Sky Biotech Boehringer Ingelheim Boehringer Ingelheim Vetmedica BostonGene Bristol-Myers Squibb Bruker Bucher Biotec Bulldog Bio c-LEcta Caladrius Biosciences Caliber Biotherapeutics California Institute for Quantitative Biosciences (QB3) Calixar Cambridge Isotope Laboratories Cambridge Research Biochemicals Camino Partnership Cancer Research Technology Cancer Research UK Cangene Caprion Biosciences Caprion Proteomics Caprotec Bioanalytics For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

SAN DIEGO--(BUSINESS WIRE)-- Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Matt Patricelli, Ph.D. has been promoted to Chief Scientific Officer. “I can’t think of a better leader for our discovery organization than Matt. He was the first employee and founding scientist at Vividion, and has since seen the evolution from an early drug discovery company to one with multiple late stage discovery programs and multiple programs moving towards the clinic,” said Aleksandra Rizo, President and Chief Executive Officer of Vividion. “Under Matt’s leadership the company has leveraged the proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. Matt’s promotion comes at an exciting inflection point in our growth and evolution into a clinical stage company.” “I am very excited to be promoted into this important role at Vividion and will be dedicated to maintaining our award-winning culture and supporting the growth of our pipeline fueled by our world-class chemoproteomics discovery platform,” said Dr. Patricelli. “I am excited to see the progress of our first-in-class programs in oncology and immunology targeting proteins the industry has previously viewed as undruggable. We believe these compounds have the potential to deliver enormous value to patients, if successful in the clinic. I am energized by the arm’s length business model established with Bayer that allows us to operate largely autonomously and independently but with the technical expertise and financial stability of a major pharmaceutical company.” Dr. Patricelli joined Vividion in 2016 and was a member of the company’s senior management team. Previously at Vividion, Dr. Patricelli was SVP of Early Discovery Sciences and led all early drug discovery efforts including target selection and validation, as well as the initial early development of Vividion’s chemical proteomics platform. In his new role, Dr. Patricelli will lead all aspects of discovery and preclinical research at Vividion. Prior to joining Vividion, Dr. Patricelli served as the Senior Director of Biology at Wellspring Biosciences where he led several drug discovery programs including the KRAS-G12C covalent inhibitor discovery project. From 2000-2012 Dr. Patricelli led the chemical proteomics platform activities at ActivX Biosciences. He was the first Scientist to join ActivX and played a key role in the development of ActivX’s platform technologies, including establishing the KiNativ platform which operated as a commercial screening service for more than 15 years. Dr. Patricelli obtained his BSc in Biochemistry from McGill University, and Ph.D. from The Scripps Research Institute as the first graduate student of Vividion’s founder Dr. Benjamin Cravatt. He is an author or co-author of more than 30 scientific publications, and multiple patents. About Vividion Vividion Therapeutics, Inc. a wholly owned and independently operated subsidiary of Bayer AG acquired in August 2021, is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit . About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to . Find more information at Follow us on Facebook: Follow us on Twitter: @BayerPharma